.

  FOR IMMEDIATE RELEASE
Contact:  

Robert F. Apple, Chief Operating Officer
InKine Pharmaceutical Company, Inc.
215-283-6850

Donald C. Weinberger
Wolfe Axelrod Weinberger Assoc. LLC
212-370-4500, 212-370-4505 fax
[email protected]


INKINE CEO TO BE INTERVIEWED ON CNBC EUROPE AND
TO PRESENT AT RODMAN & RENSHAW TECHVEST
GLOBAL HEALTHCARE CONFERENCE

 

BLUE BELL, PA PA  May 6, 2004 -- InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced that Leonard S. Jacob, M.D., Ph.D., Chairman and Chief Executive Officer of InKine will participate in a live interview on Wednesday, May 12, 2004 with CNBC Europe at 11:30am London time to discuss InKine and its product pipeline.  Following the interview, Dr. Jacob will be participating in the Rodman & Renshaw Techvest Global Healthcare Conference, to be held May 12-14, 2004 at Claridge’s Hotel in London, UK. Dr. Jacob is scheduled to speak at the conference on May 13, 2004 at 10:30am London time in The Drawing Room, and is expected to discuss the Company’s product opportunities and strategic initiatives.

InKine’s presentation will be broadcast live over the Internet. To access the webcast, click here. The webcast will be archived for 90 days

 About InKine Pharmaceutical
InKine Pharmaceutical Company, Inc. is a publicly traded specialty pharmaceutical company focused on developing and commercializing pharmaceutical products for the diagnosis and treatment of gastrointestinal disorders. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. The Company's franchise product, Visicol® is the only tablet purgative preparation indicated for bowel cleansing prior to colonoscopy. InKine's second product, IB-Stat®, is an oral hyoscyamine spray for the treatment of a variety of indications.  Additionally, the Company has filed a provisional patent application for the development of a new generation purgative, INKP-102, for which clinical trials are expected to initiate during 2004, and is developing Colirest™, which is in clinical trials for the treatment of Crohn's disease. For further information, please visit InKine on its web site http://www.inkine.com.

In addition to historical facts or statement of current condition, this press release may contain forward-looking statements. Forward-looking statements provide InKine's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings projections, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. InKine's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties such as those set forth in its reports on Form 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, InKine does not intend (and it is not obligated) to update publicly any forward-looking statements. This discussion is permitted by the Private Securities Litigation Reform Act of 1995.